Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders
{{output}}
Precise control of pre-mRNA splicing is vital for transcriptome integrity, and its disruption is an emerging cancer vulnerability. Here, we use indisulam to degrade RBM39 and show that the clinical ALK inhibitor alectinib can be repurposed to inhibit SRPK1. Co... ...
